文献速递间质性肺疾病

尼达尼布长期治疗亚洲特发性肺纤维化患者:INPULSIS-ON结果

Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
PubMed 文献 · Respirology · 2019-07-22

INPULSIS-ON扩展研究评估尼达尼布在亚洲IPF患者中的长期疗效与安全性,215例亚洲患者接受开放标签尼达尼布,中位总暴露42.2个月。结果显示FVC年下降率在INPULSIS-ON期间为-127 mL/年,腹泻事件率在继续与起始用药组分别为58.8和82.5事件/100患者暴露年。

要点

  • 尼达尼布在亚洲IPF患者中延缓疾病进展的效应长期持续。
  • 长期治疗安全性和耐受性可接受,腹泻常见但可控。
  • 亚洲患者中位总暴露42.2个月,最长64.1个月。

核心结论

  • 尼达尼布对亚洲IPF患者延缓疾病进展的效应长期持续,长期治疗安全性和耐受性可接受。

研究设计与样本

  • INPULSIS-ON为开放标签扩展试验,纳入完成INPULSIS试验的亚洲IPF患者215例,其中121例继续尼达尼布,94例起始尼达尼布(先前接受安慰剂),分析为描述性。

主要发现

  • INPULSIS-ON中亚洲患者基线平均年龄66.3岁(SD 7.5),男性80.5%,平均FVC占预计值78.9%(SD 19.3)。
  • INPULSIS试验52周内亚洲患者FVC年下降率:尼达尼布组-124 mL/年(SE 20),安慰剂组-218 mL/年(SE 24)。
  • INPULSIS-ON中192周内亚洲患者FVC年下降率为-127 mL/年(SE 11)。
  • 亚洲患者中位尼达尼布总暴露42.2个月,最大暴露64.1个月。
  • 腹泻事件率在INPULSIS-ON中继续尼达尼布组为58.8事件/100患者暴露年,起始尼达尼布组为82.5事件/100患者暴露年。

临床怎么用

  • 亚洲IPF患者可考虑长期使用尼达尼布以延缓FVC下降,需监测腹泻等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) were investigated in the placebo-controlled INPULSIS® trials. All patients who completed an INPULSIS® trial could receive open-label nintedanib in the extension trial INPULSIS®-ON. METHODS: We assessed the long-term efficacy and safety of nintedanib in patients of Asian race who were treated in INPULSIS®-ON. Analyses were descriptive. RESULTS: A total of 215 Asian patients were treated in INPULSIS®-ON, of whom 121 continued nintedanib in INPULSIS®-ON and 94 initiated nintedanib in INPULSIS®-ON having received placebo in an INPULSIS® trial. At baseline of INPULSIS®-ON, the mean (SD) age of Asian patients was 66.3 (7.5) years, 80.5% were males and mean (SD) forced vital capacity (FVC) was 78.9 (19.3) % predicted. Median total exposure to nintedanib in both INPULSIS® and INPULSIS®-ON was 42.2 months; maximum exposure was 64.1 months. In INPULSIS®, the annual rate (SE) of decline in FVC over 52 weeks in Asian patients was -124 (20) mL/year in the nintedanib group and -218 (24) mL/year in the placebo group. In INPULSIS®-ON, the annual rate (SE) of decline in FVC over 192 weeks in Asian patients was -127 (11) mL/year. Diarrhoea was reported in Asian patients at event rates of 58.8 and 82.5 events per 100 patient exposure-years in patients who continued and initiated nintedanib in INPULSIS®-ON, respectively. CONCLUSION: The effect of nintedanib on slowing disease progression in Asian patients with IPF is sustained over the long term. Long-term treatment with nintedanib has an acceptable safety and tolerability profile.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Song JW, Ogura T, Inoue Y, et al. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON. Respirology. 2019. PMID: 31329360. doi:10.1111/resp.13647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。